Source: Virtual Congress 2020 – From respiratory physiology to diagnosis and treatment
Disease area: Sleep and breathing disorders



Rating:

Share or cite this content

Citations should be made in the following way:
I. Bouloukaki (Heraklion (Crete), Greece), M. Bonsignore (Palermo, Italy), L. Grote (Gothenburg , Sweden), W. Mcnicholas (Dublin, Ireland), J. Hedner (Gothenburg, Sweden), J. Verbraecken (Antwerp, Belgium), S. Ryan (Dublin, Ireland), C. Lombardi (Milan, Italy), O. Basoglu (Izmir, Turkey), A. Pataka (Thessalononiki, Greece), O. Marrone (Palermo, Italy), S. Bailly (Grenoble, France), J. Pepin (Grenoble, France), P. Steiropoulos (Alexandroupolis, Greece), S. Schiza (Heraklion, Greece). The sleepy phenotype in mild OSA patients: characteristics and their cardiometabolic risk. Data from the European Sleep Apnea Data Base (ESADA). 2565

Member's Comments

No comment yet.

Related content which might interest you: The sleepy phenotype in mild Obstructive  Sleep Apnoea (OSA) patients: from clinical characteristics to cardiometabolic risk. Data from the European Sleep Apnea Database (ESADA). Source: Virtual Congress 2021 – From phenotyping to different diagnostic tools for sleep breathing disorders Year: 2021 Obstructive sleep apnea is an independent predictor for dyslipidemia: Data from the European Sleep Apnea Database (ESADA) Source: International Congress 2017 – Central sleep apnoea: consequences and comorbidities of obstructive sleep apnoea Year: 2017 The effect of positive airway pressure on cholesterol in patients with sleep apnea: Data from the European Sleep Apnea Network (ESADA) Source: International Congress 2019 – Current perspectives in sleep-disordered breathing Year: 2019 Determinants of daytime sleepiness in mild obstructive sleep apnoea syndrome. Data from the European Sleep Apnoea Database (ESADA) cohort study. Source: International Congress 2018 – Sleep-disordered breathing: cardiovascular consequences, epidemiology, phenotypes and comorbidities Year: 2018 Hyperlipidemia Prevalence and Cholesterol Control in OSA: Data from European Sleep Apnea Database (ESADA) Source: International Congress 2019 – Challenging issues in the clinical aspects of sleep-disordered breathing Year: 2019 Prevalence of metabolic syndrome (MS) in a population of apneic patients:A prospective study with cardiovascular risk estimation Source: International Congress 2014 – Sleep disordered breathing 4 Year: 2014 Regional differences in characteristics of patients referred to European sleep centers. Results from the European Sleep Apnea Database (ESADA) Source: Annual Congress 2012 - Paediatrics and sleep apnoea/adults and upper airway stimulation Year: 2012 Change in weight and central obesity by positive airway pressure treatment in obstructive sleep apnea patients: Longitudinal data from the European Sleep Apnea Database (ESADA) Source: International Congress 2017 – Efficacy of and compliance with obstructive sleep apnoea treatment Year: 2017 OSA and cancer in Europe: the European Sleep Apnea Database (ESADA) experience Source: International Congress 2017 – Central sleep apnoea: consequences and comorbidities of obstructive sleep apnoea Year: 2017 Sleep apnoea management in Europe during the COVID-19 pandemic: data from the European Sleep Apnoea Database (ESADA) Source: Eur Respir J, 55 (6) 2001323; 10.1183/13993003.01323-2020 Year: 2020 The European Sleep Apnoea Database (ESADA): report from 22 European sleep laboratories Source: Eur Respir J 2011; 38: 635-642 Year: 2011 LATE-BREAKING ABSTRACT: The Sleep Apnea cardioVascular Endpoints (SAVE) study results – A trial of CPAP versus usual care in 2717 high cardiovascular risk patients with moderate-severe obstructive sleep apnea (OSA) Source: International Congress 2016 – Cardiovascular and metabolic pathophysiology and outcomes of obstructive sleep apnoea Year: 2016 Impact of speed and age on an office based advanced driving simulator (MinUoLDS) between obstructive sleep apnoea syndrome (OSAS) patients and controls Source: International Congress 2014 – Sleep disordered breathing 2 Year: 2014 The effect of CPAP withdrawal on blood pressure in OSA: Data from three randomised-controlled trials Source: International Congress 2014 – The story continues: impact of OSA on cardiometabolic parameters Year: 2014 Evaluation of cognitive dysfunction using the cognitive failures questionnaire (CFQ), driving incidents and driving simulator (MiniUoLDS) outcome in obstructive sleep apnoea syndrome (OSAS) patients and controls Source: International Congress 2014 – The technical and diagnostic agenda in OSA Year: 2014 Obstructive sleep apnea and cardiovascular risk markers in community individuals- Results from the sleep apnea and vascular evaluation (SAVE) study Source: International Congress 2016 – Effects of hypoxia and sleep apnoea on the lung, heart, and vessels Year: 2016 Prevalence of obstructive sleep apnea syndrome in patients with risk factors for cardiovascular diseases in a large population in Zaragoza (Spain) Source: International Congress 2014 – Sleep disordered breathing 3 Year: 2014 Residual daytime sleepiness (RES) in CPAP-treated obstructive sleep apnea (OSA) patients in the European Sleep Apnea Database (ESADA) Source: Virtual Congress 2021 – From phenotyping to different diagnostic tools for sleep breathing disorders Year: 2021 Comparing coping strategies, accident history and driving simulator (MiniUoLDS) outcome in obstructive sleep apnoea syndrome (OSAS) patients and controls Source: International Congress 2014 – Sleep disordered breathing 2 Year: 2014 Identification of subjects with high probability of sleep-disordered breathing in a non-sleepy general population: The NoSAS score Source: International Congress 2015 – Paediatric and adult sleep-disordered breathing: from inflammation to treatment and telemedicine Year: 2015